It's not quite as scathing as previous commentary from the motley fool http://www.********.au/2015/03/02/s...-an-all-time-low-is-this-small-cap-a-bargain/
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
